Compare BMEA & ATLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMEA | ATLX |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 124.5M |
| IPO Year | 2021 | 2012 |
| Metric | BMEA | ATLX |
|---|---|---|
| Price | $1.40 | $4.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $9.83 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.2M | 909.6K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.19 | 47.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $92,491.00 |
| Revenue This Year | N/A | $64,564.67 |
| Revenue Next Year | N/A | $785.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $3.60 |
| 52 Week High | $3.07 | $8.25 |
| Indicator | BMEA | ATLX |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 44.07 |
| Support Level | $1.23 | $3.97 |
| Resistance Level | $1.45 | $5.04 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 47.57 | 14.35 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.